Redmile Group, a hedge fund and private equity manager, led a $95m Series C funding round in Evox Therapeutics, a developer of exosome-based therapeutics, with participation from OrbiMed, Invus, Oxford Sciences Innovation, GV and Cowen Healthcare Investments. "We are delighted with the support received in this Series C financing from both our existing investors and our new investors. The level of interest in this financing round is testament to the progress we have made over the last few years. Since our Series B round in 2018, we have continued to develop our DeliverEXTM platform, advance our pipeline of exosome therapeutics, expand our intellectual property portfolio, build our R&D capabilities and bolster our management team. We have also signed significant partnership deals with Eli Lilly and Takeda, two of the world's leading pharma companies. We welcome Chau Khuong to our Board and look forward to his contributions as Evox enters its next phase of growth," Antonin de Fougerolles, Evox CEO.